Gallant Joel E, Koenig Ellen, Andrade-Villanueva Jaime F, Chetchotisakd Ploenchan, DeJesus Edwin, Antunes Francisco, Arastéh Keikawus, Rizzardini Giuliano, Fehr Jan, Liu Hui C, Abram Michael E, Cao Huyen, Szwarcberg Javier
*Southwest CARE Center, Santa Fe, NM; †Inst. Dominicano de Estudios Virologicos, Santo Domingo, Dominican Republic; ‡HIV Unit, Hospital Civil de Guadalajara, Guadalajara, Mexico; §Department of Medicine, Khonkaen University, Khonkaen, Thailand; ‖Orlando Immunology Center, Orlando, FL; ¶Instituto de Saúde Ambiental, Faculdade de Medicina de Lisboa, Lisbon, Portugal; #EPIMED, Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; **Infectious Diseases Department, "Luigi Sacco" Hospital, Milan, Italy; ††Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; and ‡‡Gilead Sciences, Inc., Foster City, CA.
J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):338-40. doi: 10.1097/QAI.0000000000000598.
Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity.
International, randomized double-blind active-controlled trial to evaluate the efficacy and safety of COBI vs ritonavir (RTV) as a pharmacoenhancer of atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV treatment-naive patients followed through week 144.
At Week 144, virologic suppression was achieved in 72% (COBI) and 74% (RTV) of patients. Adverse events leading to study drug discontinuation occurred in 11% of patients in each group. Median changes in serum creatinine (mg/dL) were +0.13 (COBI) and +0.07 (RTV) and were unchanged from week 48.
Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor atazanavir.
考比司他（COBI）是一种无抗逆转录病毒活性的药物增强剂。
一项国际随机双盲活性对照试验，旨在评估在初治HIV患者中，COBI与利托那韦（RTV）作为阿扎那韦的药物增强剂与恩曲他滨/富马酸替诺福韦二吡呋酯联合使用至144周时的疗效和安全性。
在第144周时，72%（COBI）和74%（RTV）的患者实现了病毒学抑制。每组中因不良事件导致停用研究药物的患者比例均为11%。血清肌酐（mg/dL）的中位数变化在COBI组为+0.13，在RTV组为+0.07，与第48周时相比无变化。
每日一次的COBI是蛋白酶抑制剂阿扎那韦的一种安全有效的药物增强剂。
